Subscribe
CI Photos / Shutterstock.com
12 June 2025NewsBiotechnologyLiz Hockley

Synthego clears rival’s patents from CRISPR market at Fed Circ

Judges uphold PTAB’s finding that two Agilent patents are invalid | All claims of patents, which cover guide RNAs, found to be anticipated by prior art.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Federal Circuit revives CRISPR feud citing PTAB errors
13 May 2025   Court partially overturns PTAB decision favouring Broad Institute in the long-running gene-editing patent dispute | Case sent back to clarify invention conception | Third parties face "yet more delays" in a patent landscape that appears "constantly in flux".
Europe
South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug
22 April 2025   Gene editing company ToolGen “seeks fair licensing agreement” for alleged infringement by rival | High-value sickle cell treatment CASGEVY was “born from ToolGen’s proprietary CRISPR RNP tech” says complaint | Potter Clarkson instructed.
Biotechnology
The new IP battleground in CRISPR-Cas
21 November 2023   Recent clashes over patents covering modified guide RNAs have exposed different approaches from the US and Europe—and new complications for the field, says Claire Irvine of HGF.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Americas
Federal Circuit revives CRISPR feud citing PTAB errors
13 May 2025   Court partially overturns PTAB decision favouring Broad Institute in the long-running gene-editing patent dispute | Case sent back to clarify invention conception | Third parties face "yet more delays" in a patent landscape that appears "constantly in flux".
Europe
South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug
22 April 2025   Gene editing company ToolGen “seeks fair licensing agreement” for alleged infringement by rival | High-value sickle cell treatment CASGEVY was “born from ToolGen’s proprietary CRISPR RNP tech” says complaint | Potter Clarkson instructed.
Biotechnology
The new IP battleground in CRISPR-Cas
21 November 2023   Recent clashes over patents covering modified guide RNAs have exposed different approaches from the US and Europe—and new complications for the field, says Claire Irvine of HGF.

More on this story

Americas
Federal Circuit revives CRISPR feud citing PTAB errors
13 May 2025   Court partially overturns PTAB decision favouring Broad Institute in the long-running gene-editing patent dispute | Case sent back to clarify invention conception | Third parties face "yet more delays" in a patent landscape that appears "constantly in flux".
Europe
South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug
22 April 2025   Gene editing company ToolGen “seeks fair licensing agreement” for alleged infringement by rival | High-value sickle cell treatment CASGEVY was “born from ToolGen’s proprietary CRISPR RNP tech” says complaint | Potter Clarkson instructed.
Biotechnology
The new IP battleground in CRISPR-Cas
21 November 2023   Recent clashes over patents covering modified guide RNAs have exposed different approaches from the US and Europe—and new complications for the field, says Claire Irvine of HGF.

More features

UPC promises CMS overhaul with new phased release
Vidal: Coke Morgan Stewart's rulings are 'taxing innovation'
Sheppard Mullin expands practice with Perkins Coie trio
Fed Circ affirms rulings in Acadia’s fight against Parkinson’s drug copies
USPTO’s Stewart: Don’t nix patents as penalty for misconduct
Fed Circ upholds Moderna’s COVID-19 vaccine win against Alnylam
‘Choose your IP armour carefully’: Novartis, HP, Nestlé and Vidal
Wilson Sonsini adds veteran USPTO examiner as senior patent counsel